The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the
disease COVID-19 can lead to serious symptoms, such as severe pneumonia, in the elderly …

Multiple new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have constantly emerged, as the delta and omicron variants, which have developed …

SARS-CoV-2 infection results in viral burden in the respiratory tract, enabling transmission
and leading to substantial lung pathology. The 1212C2 fully human monoclonal antibody …

Prevention of SARS-CoV-2 infection at the point of nasal entry is a novel strategy that has
the potential to help contain the ongoing pandemic. Using our proprietary technologies, we …

The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019
(COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed …

Despite the recent availability of vaccines against severe acute respiratory syndrome
coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 …

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
currently the biggest healthcare issue worldwide. This study aimed to develop a monoclonal …

The emergence of COVID-19 has led to a pandemic that has caused millions of cases of
disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by a burst
in the upper respiratory portal for high transmissibility. To determine human neutralizing …

SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …